Zhitong Financial App News, Betta Pharmaceuticals (300558.SZ) announced today that its partner EyePoint, Inc. (NASDAQ: EYPT, “EyePoint”) announced the data results of the second key phase III clinical trial LUCIA to develop voronibu ophthalmic preparation EYP-1901 (DURAVYU™, “DURAVYU” for short) to treat wet age-related macular degeneration (“WamD”). The study did not reach its intended primary endpoint, and although there was an improvement in eyesight in the DURAVYU treatment group, it was not statistically inferior in terms of the average change in optimal corrected visual acuity (BCVA) from baseline compared to the 2 mg control group with abacept. Key secondary endpoints such as safety, reduction in treatment burden, no need for supplementary treatment rates, and anatomical control have all been achieved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.